Poxel commences its Phase 1b trial for NASH drug candidate, PXL065
Category: #health  By Paroma Bhattacharya  Date: 2019-09-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Poxel commences its Phase 1b trial for NASH drug candidate, PXL065

Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by the buildup of fat in the liver mostly with people who drink little or no alcohol. With growing cases of NASH prevailing worldwide, pharmaceutical companies are now focusing on developing new drugs by means for novel clinical trials.

POXEL SA, a biopharmaceutical company that develops advanced treatments for metabolic disorders like non-alcoholic steatohepatitis (NASH), recently made some strides in this field with its Phase 1b randomized, double-blind, placebo-controlled trial in fit candidates to understand the tolerability, pharmacokinetics (PK) and safety of PXL065 (DRX-065).

According to reliable sources, this trial intends to confirm the predicted dose proportionality and relative exposure of the PXL065 (DRX-065), a drug developed to treat patients with noncirrhotic NASH by targeting MPC (mitochondrial pyruvate carrier) inhibition. PXL065 is claimed to have the potential to offer a better therapeutic than 45 mg of Actos®* (pioglitazone).

For the record, pioglitazone was comprehensively researched in NASH with demonstrated effectiveness, but its use is very restricted because of its side effects, like fluid retention and weight gain, which might be linked with the S-stereoisomer.

Commenting on the study, Thomas Kuhn, CEO, Poxel, said that the company’s in-depth knowledge of the cellular energy regulation related to metabolic disorders, like NASH, has immensely assisted it to accelerate the quick development of various pipeline along with two positive clinical programs still in the developing stage for treating this chronic metabolic disease.

He added that according to phase 1 and preclinical results, PXL065 comes out as a promising medicine that shows an improved therapeutic profile when rivaled with pioglitazone for noncirrhotic NASH patients.

Reportedly, Poxel has also made some advances towards treating type 2 diabetes which it disclosed in its recent conference at the 55th Annual Meeting of the EASD (European Association for the Study of Diabetes), conducted in Barcelona, Spain.

The session focused on discussing the medicinal potential of the company’s most promising drug candidate, Imeglimin, a modern treatment focusing on type 2 diabetes in several patient populations, and detailed Phase 3 TIMES 1 outcomes in Japanese patients.

Source Credit: https://www.poxelpharma.com/en_us/news-media/press-releases/detail/127/poxel-initiates-phase-1b-multiple-ascending-dose-mad



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...